GlassScriptPhysician profile
Hillary Daugherty
NPI 1265994842
$4,199.44
in general payments reported to CMS, 2019-2025
46 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.29 · 2022: $24.20 · 2023: $224 · 2024: $1,433 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,092 · Education: $70.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,091.91 |
| Education | $70.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $346.02 | 2023-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $320.96 | 2024-2025 | |
| Celgene Corporation | $307.15 | 2024-2025 | Reblozyl, Breyanzi, Opdualag |
| Astrazeneca Pharmaceuticals LP | $275.50 | 2023-2025 | Imfinzi, Lynparza |
| Astellas Pharma US INC | $218.33 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Genzyme Corporation | $216.72 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.04 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $190.01 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $181.07 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Alexion Pharmaceuticals, INC. | $138.45 | 2023-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $127.30 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $109.83 | 2024-2025 | Xpovio |
| Taiho Oncology, INC. | $102.74 | 2025 | |
| Aveo Pharmaceuticals, INC. | $95.04 | 2025 | |
| Sobi, INC | $91.08 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.29 | 2023-2025 | |
| Pharmaessentia USA Corporation | $87.04 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $78.37 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $78.16 | 2024-2025 | Opdivo |
| Daiichi Sankyo INC. | $74.31 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Sanofi-Aventis U.S. LLC | $73.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $72.76 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $70.37 | 2025 | Libtayo |
| Novo Nordisk INC | $67.77 | 2022-2025 | Esperoct |
| Genentech USA, INC. | $66.27 | 2024-2025 | Venclexta, Columvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.11 | 2025 | |
| Abbvie INC. | $38.85 | 2025 | |
| Array Biopharma INC | $37.01 | 2024 | Braftovi, Mektovi, Lorbrena |
| Genmab U.S., INC. | $36.63 | 2025 | Epkinly |
| Puma Biotechnology, INC. | $31.50 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.34 | 2024 | Somatuline Depot, Onivyde |
| Geron Corporation | $23.01 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $22.47 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $20.53 | 2024 | Sylvant |
| Blueprint Medicines Corporation | $19.80 | 2024 | Ayvakit |
| Emmaus Medical, INC. | $18.46 | 2025 | Endari |
| Lilly USA, LLC | $18.43 | 2025 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $18.19 | 2025 | Yescarta |
| Exelixis INC. | $18.12 | 2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $17.87 | 2025 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $14.82 | 2025 | Givlaari |
| Seagen INC. | $13.79 | 2023 | Adcetris |
| Caris Mpi, INC. | $13.72 | 2025 | Mi Cancer Seek |
| Springworks Therapeutics, INC. | $13.60 | 2025 | Ogsiveo |
| Foundation Medicine, INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.